Otsuka's Voyxact met Phase 3 VISIONARY endpoint in IgAN; BioNTech cuts revenue forecast; Lisata sues Kuva Labs; and more
August 4, 2026 10:50 AM EDT
Otsuka succeeds with kidney drug; BioNTech downgrades revenue projection
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Confirm Endpoints as a trusted biopharma news source
In a first, Otsuka’s Voyxact stabilizes IgAN patients’ kidney function decline to normal levels
Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy (IgAN)
Novartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer
Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis
